TY  - JOUR
TI  - Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
AB  - OBJECTIVE: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response. METHODS: CXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls. RESULTS: Fingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MSSCON patients. CONCLUSION: Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.
AU  - Karaaslan, Zerrin
AU  - YILMAZ, VUSLAT
AU  - Yüceer, Hande
AU  - Şanlı, Elif
AU  - AKCAY, halil ibrahim
AU  - Türkoğlu, Recai
AU  - Tuzun, Erdem
AU  - Kürtüncü, Murat
DO  - 10.14744/nci.2022.77861
PY  - 2023
JO  - İstanbul Kuzey Klinikleri
VL  - 10
IS  - 3
SN  - 2148-4902
SP  - 341
EP  - 344
DB  - TRDizin
UR  - http://search/yayin/detay/1189860
ER  -